What is IPSS in MDS?
International prognosis scoring system (IPSS) in myelodysplastic syndrome. Variable. Score.
What is IPSS R?
The IPSS-R, which is the most commonly used scoring system, is a refinement of the original International Prognostic Scoring System (IPSS) based on a much larger clinical database (N=7012). 1. The IPSS-R considers 5 variables1: Percentage of bone marrow (BM) blasts. Karyotype.
What is secondary MDS?
Secondary MDS occurs because of damage to the DNA from chemotherapy or radiation therapy previously given to treat another medical condition. MDS can develop 2 to 10 years after such treatment. Secondary MDS is often associated with more complex chromosomal abnormalities.
What is cytogenetic category?
For cytogenetic prognostic categorization, chromosomal abnormalities were classified into six different cytogenetic categories: normal karyotype, trisomy 8 (alone or with one additional abnormality), isolated loss of Y chromosome, complex karyotype (three or more abnormalities), anomalies of chromosome 7 (monosomy 7 or …
What is a prognostic score?
The prognostic score, formalized by Hansen [5], is defined as the predicted outcome under the control condition, reflecting baseline “risk.” It is estimated by fitting a model of the outcome in the control group and then using that model to obtain predictions of the outcome under the control condition for all …
What is blast percentage in MDS?
MDS-EB1: blasts make up 5% to 9% of the cells in the bone marrow, or 2% to 4% of the cells in the blood. MDS-EB2: blasts make up 10% to 19% of the cells in the bone marrow, or 5% to 19% of the cells in the blood.
What is cytogenetic risk?
Based on outcome analysis, three cytogenetic risk categories were identified: low risk (normal karyotype or loss of Y chromosome as a single anomaly), high risk (presence of trisomy 8 or abnormalities of chromosome 7, or complex karyotype), and intermediate risk (all other abnormalities).
Is MDS a terminal illness?
MDS is a form of bone marrow cancer, although its progression into leukaemia does not always occur. The failure of the bone marrow to produce mature healthy cells is a gradual process, and therefore MDS is not necessarily a terminal disease. In some patients, however, MDS can progress to AML, Acute Myeloid Leukaemia.
What is prognostic risk?
Prognostic factors are similar to risk factors in conventional cohort studies, but they may occur at a different stage on the disease spectrum: risk factors are present before the development of a disease, whereas prognostic factors may either have been present before the onset (e.g. sex, smoking behaviour) of the …
How are patients in the IPSS-R subgroups classified?
Data indicated that 99% of the patients in the IPSS-R Very low and Low risk subgroups encompassed those who had been classified as IPSS Low and Intermediate-1; 81% of those in the IPSS-R High and Very high risk subgroups had been classified as IPSS Intermediate-2 and High (Figure 7, Kendall tau = 0.73).
What is the revised-IPSS [IPSS-R]?
To refine the IPSS, MDS patient databases from international institutions were coalesced to assemble a much larger combined database (Revised-IPSS [IPSS-R], n = 7012, IPSS, n = 816) for analysis. Multiple statistically weighted clinical features were used to generate a prognostic categorization model.
Can we use IPSS-R to predict outcomes of untreated myelodysplastic syndromes?
As such, this IPSS-R should prove beneficial for predicting the clinical outcomes of untreated MDS patients and aiding design and analysis of clinical trials in this disease. The myelodysplastic syndromes (MDS) consist of a heterogeneous spectrum of myeloid clonal hemopathies.
How many patients are there in the combined IWG-pm database?
After careful vetting for accuracy, a combined IWG-PM database of 7012 patients, classified morphologically by FAB (n = 7000) and, in most cases, by the WHO criteria (n = 5504), 6 was created.